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stratiﬁed by the stage of disease. RESULTS: Annual outpatient costs per patient were 
694; 877; and US$1409 for Qingdao, Nanjing, and Beijing, respectively. Among out-
patient expenses, western medications formed the bulk of these costs in Qingdao 
(58.9%) and Beijing (62.9%), but a lesser amount in Nanjing (46.9%). The use of 
antivirals is 20% in Nanjing and 37% in Qingdao of total western medications. TCM 
prescriptions for CHB varied across these different cities with the greatest usage in 
Nanjing (20.8%). For hospitalized patients, annual costs per patient were 1893; 2101, 
and US$2622 in Nanjing, Qingdao, and Beijing, respectively. The costs increased 
progressively in patients with compensated liver disease, (US$1983) decompensated 
liver disease (US$2802) and hepatocellular cancer (US$3019), respectively. Patients 
contributed around 50% towards outpatient costs and 30% towards inpatient care. 
CONCLUSIONS: CHB exerts a signiﬁcant health and ﬁnancial burden which progres-
sively increases as patients progress from early to late stages of the disease. While 
antivirals are associated with a reduction in disease progression, their use remains 
relatively low in urban areas in China. Further work is required to determine whether 
an early treatment with effective CHB medications can reduce the overall ﬁnancial 
burden within China.
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OBJECTIVES: Outbreaks of inﬂuenza often incur a substantial burden in terms of 
health care utilization, health care costs and societal costs. The aim of this analysis 
was to identify gaps in available data related to the economic burden of inﬂuenza in 
children in the UK, Germany, Italy, Spain, France, Sweden, The Netherlands, Finland, 
and Austria. METHODS: A structured literature search (1970-March 2009) involving 
PubMed, EMBASE, and the Cochrane Library formed the basis of the gap analysis. 
Articles were excluded if not related to inﬂuenza and not reporting resource use, cost, 
absenteeism or utility data in a country of interest for a group a18 years. A total of 
171 articles were short-listed for full-text review, and data extracted from 43. 
RESULTS: Available published data suggests a signiﬁcant burden of inﬂuenza in chil-
dren. Most studies reporting health care utilization (31 of 32) focused on hospitaliza-
tion, clinician visits, and prescription of antibiotics, antipyretics, or analgesics. 
Regarding cost burden of inﬂuenza, the number of studies speciﬁcally related to the 
pediatric population was small, and rarely included a breakdown by age group and 
disease severity. Absenteeism data focused on missed days at day care/school or 
parental lost work days. Little information was reported on household contacts or on 
reductions in productivity. Studies reporting impact on quality of life were very 
limited. Burden information is fragmented and incomplete. Only for Italy, France, and 
Spain are data available from multiple studies speciﬁc to a pediatric cohort. CONCLU-
SIONS: Existing information suggests a signiﬁcant burden of inﬂuenza in children. 
Burden information across reviewed EU countries is incomplete and fragmented. A 
multinational data collection initiative providing a complete and age-stratiﬁed picture 
of the burden of inﬂuenza in children appears warranted.
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OBJECTIVES: Anti-venom is the only speciﬁc treatment to prevent neurological dis-
orders, amputation and death in snakebite envenoming, categorized as neglected 
tropical disease by WHO. Majority of victims are young and economically productive. 
Hence, the economic impact of their disability is considerable. We reviewed the burden 
and cost of snakebite envenoming: its incidence, morbidity and mortality rates, and 
the access to anti-venom treatment. METHODS: The information was retrieved from 
1985–2009 from MEDLINE, Google Scholar and WHO website with search terms 
including “snakebite”, “antivenom”, “cost of antivenom” and “snakebite morbidity 
and mortality”. RESULTS: Snakebite as a tropical disease causes considerable morbid-
ity and mortality worldwide with global annual estimates for 2007 ranging from 
1,200,000–5,500,000 for snakebite incidence to 42,1000–1,841,000 and 20,000–
94,000 for envenoming and deaths respectively. South Asia (121,000) has the highest 
number of envenoming followed by Southeast Asia (111,000) and east-Sub-Saharan 
Africa (43,000). The price of anti-venom has typically risen by 10 fold over the last 
20 years. For example, the costs to Australian hospitals of CSL polyvalent and taipan 
antivenoms were A$1833 and A$1577 in 2003 as compared to A$300 and A$245 in 
1985, respectively. The number of anti-venom vials increases with severity (upto 5, 
10 and 20 for mild, moderate and severe cases respectively) thereby increasing cost 
of treatment. Inadequate anti-venom supply further exaggerates this problem as the 
current annual need amounts to 10,000,000 vials. Incidence is higher in rural areas, 
where incomes are generally lower. In Nepal, out-of-pocket expenses (US$69) equal 
several months of income as most people have a daily incomes of 1–2 US$, besides 
15 days of working incapacity period. CONCLUSIONS: The excessive cost and 
inadequate supply of anti-venom renders it inaccessible to most people in developing 
countries. Appropriate measures should be taken to prevent the clinical and economic 
impact of this neglected disease.
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OBJECTIVES: Despite a signiﬁcant decrease over the last 20 years, the prevalence of 
hepatitis B remains high in Portugal (an estimated 36,000 cases in 2002). Hepatitis B 
represents a relevant public health issue due to its dramatic consequences when it turns 
chronic, namely the associated risk of cirrhosis and hepatocellular carcinoma. The aim 
of this study was to estimate annual cost of disease states associated with chronic 
hepatitis B (CHB) from the perspective of Portuguese NHS. METHODS: We estimated 
the resource use to treat CHB and its disease states, namely Compensated Cirrhosis 
(CC), Decompensated Cirrhosis (DC), Hepatocellular Carcinoma (HCC) and Liver 
Transplantation follow-up (LT).A panel of 8 specialists from Portuguese NHS hospi-
tals were surveyed using a modiﬁed Delphi technique. Data were collected for outpa-
tient visits, laboratory tests, diagnostic and therapeutic procedures, drugs (excluding 
antivirals) and hospitalisations. RESULTS: The resource use for all categories increases 
with severity of disease. Estimated average annual costs are a1,125 for CHB, a1,761 
for CC, a18,278 for DC and a26,388 for HCC. Cost for LT procedure within Portu-
guese DRG is estimated at a100,785, while average post-LT costs are estimated at 
a30,540 and a24,780 for the ﬁrst and subsequent years, respectively. Costs for CHB 
and CC are mainly due to outpatient visits and serology tests. By contrast, inpatient 
days are the main driver of costs for DC (79%), HCC (50%) and post-LT in the ﬁrst 
year after treatment (71%). Drugs represent the second major component of costs for 
HCC (18%), and post-LT in the ﬁrst (23%) and second (72%) year, related to immu-
nosuppressants and hepatitis B immunoglobulin respectively. CONCLUSIONS: Our 
study shows that annual costs of managing CHB disease states are high and increase 
substantially with disease severity. Both economic arguments and public health ones 
point to the necessity to control CHB infection and its progression.
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OBJECTIVES: Poor adherence is a serious issue in the management of patients with 
chronic hepatitis C (CHC) owing to the difﬁculty of treatment with pegylated inter-
feron/ribavirin (Peg-IFN/RBV). Future small molecule treatments may obviate difﬁcul-
ties of Peg-IFN/RBV therapy. We analyzed cohorts of CHC patients treated with 
Peg-IFN/RBV to quantify the impact of medication adherence on health care costs 
over 4 years follow-up. METHODS: A retrospective claims analysis was performed 
from January 1, 2001 through December 31, 2007 using the Medstat MarketScan 
database. Inclusion criteria: 1) CHC patients greater than 18 years; 2) who initiated 
Peg-IFN/RBV treatment in 2002 (index); and 3) continued for greater than 24 weeks 
from index. Continuous enrollment from 6 months prior to index (baseline) to 48 
weeks after index (follow-up) was required. Patients were excluded if they had a 
diagnosis of HIV or HBV. Adherence was deﬁned by medication possession ratio 
(MPR), days with Peg-IFN/RBV divided by 336 days or 48 weeks. Overall Medical 
and Pharmacy costs were compared between adherent (MPR q 80%) versus non-
adherent patients (MPR  80%), controlling for age, gender and baseline costs. 
RESULTS: A total of 1173 patients met study inclusion criteria (adherent, n  319; 
non-adherent, n  854). The majority of patients were male (64.5%); the mean age 
was 47 years. Univariate analysis revealed that Overall Medical, ER, Inpatient and 
Outpatient Hospitalizations, and Pharmacy costs were signiﬁcantly greater (P a 0.05) 
in non-adherent compared to adherent patients. Multivariate analysis conﬁrmed these 
results (difference in mean; 95% CI) for Overall Medical ($10,006; 1530–18,482) and 
Outpatient Hospitalization ($3,024; 553–5,494) costs. CONCLUSIONS: Medication 
non-adherence to Peg-IFN/RBV treatment was associated with greater health care 
costs. These results may be due to decreased Sustained Viral Response associated with 
low adherence. Treatment with future small molecules may potentially improve adher-
ence and reduce costs.
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OBJECTIVES: To quantify and compare the impact of using different methods for 
measuring indirect cost on the total disease cost in the economic assessment of 7-valent 
pneumococcal conjugate vaccines (PCV-7) versus pneumococcal non-typeable Hae-
mophilus inﬂuenzae protein-D conjugate vaccine (PHiD-CV) in Germany.   METHODS: 
Five different ways of using the human capital (HCM) and friction cost method (FCM) 
for estimating indirect cost have been incorporated into an age-compartmental, one-
year cross-sectional, vaccine steady-state, population-based model assessing the 
